Stelara

Ustekinumab

Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,[5] targeting both IL-12 and IL-23.[6] Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to m...

Are you a patient with moderate to severe psoriasis that is currently taking or has taken biologic therapies in the past? If so, The Frankel Group, a life science strategy consulting firm in New York City, is conducting market research to understand the experiences patients have had with biologic therapies, including Enbrel, Humira, Remicade, or Stelara. We are currently looking for patients to participate in a 30 minute market research telephone interview, for a $50 honorarium. Interviews are completely confidential and we will never share your name or information. If you are interested in participating in this market research study, please contact [email protected] or 212-896-1662 for additional details. Thank you! ## Hi Rita - how long is this study running for? Do respondents ...

3 REPLIES

Ustekinumab-auub

Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,[5] targeting both IL-12 and IL-23.[6] Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to m...

Drug Index

Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,[5] targeting both IL-12 and IL-23.[6] Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to m...

NDC Database

Stelara 130 mg/26ml Intravenous Solution by Janssen Biotech, Inc. ## Package Codes: 57894-054-16, 57894-054-27 ## Active Ingredients: Ustekinumab

NDC Database

Stelara 45 mg/.5ml Subcutaneous Injection, Solution by Janssen Biotech, Inc. ## Package Codes: 57894-060-02, 57894-060-03, 57894-060-04 ## Active Ingredients: Ustekinumab

NDC Database

Stelara 90 mg/ml Subcutaneous Injection, Solution by Janssen Biotech, Inc. ## Package Codes: 57894-061-02, 57894-061-03, 57894-061-04 ## Active Ingredients: Ustekinumab